Investigational CRISPR therapy succeeds in patient with drug-resistant E. Coli

positiveSNIPR001Positive

AI Analysis

Summary

CRISPR Therapeutics' investigational CRISPR therapy SNIPR001 demonstrated success in a patient with drug-resistant E. coli infection administered under a single-patient emergency IND authorization.

Outcome Details

CRISPR therapy SNIPR001 succeeded in patient with drug-resistant E. coli administered under single-patient emergency IND

Importance:4/10

Sentiment:

0.60

CRISPRgene therapyinfectious diseaseemergency INDsingle-patientE. coli

Related Companies

$CRSP

Read the original article

Published by Pharmaceutical Technology on August 12, 2026 10:19 AM

Read Original